Article citationsMore >>

Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 2006; 50 (8): 684-710.

has been cited by the following article:

Article

200 U vs 300 U Botulinum Toxin A Injections for Patients with Neurogenic Detrusor Overactivity Secondary to Spinal Cord Injury

1Department of Urology in Guangdong Provincial Work Injury Rehabilitation Hospital, Guangdong, China

2Departments of Emergency, the Eighth Hospital of Guangzhou, Guangdong, China


American Journal of Medical Case Reports. 2019, Vol. 7 No. 10, 250-252
DOI: 10.12691/ajmcr-7-10-7
Copyright © 2019 Science and Education Publishing

Cite this paper:
Lin JM, Chen Hui, Liu QL, Huang MP, Li QQ, Huang TH, Yang XY. 200 U vs 300 U Botulinum Toxin A Injections for Patients with Neurogenic Detrusor Overactivity Secondary to Spinal Cord Injury. American Journal of Medical Case Reports. 2019; 7(10):250-252. doi: 10.12691/ajmcr-7-10-7.

Correspondence to: Chen  Hui, Department of Urology in Guangdong Provincial Work Injury Rehabilitation Hospital, Guangdong, China. Email: doc.chenhui@163.com

Abstract

Objective: To evaluate the d the safety and efficacy of 200 U vs 300 U botulinum toxin A (BTX-A) injections for patients with neurogenic detrusor overactivity (NDO) secondary to spinal cord injury (SCI). Methods: we retrieved the data for the patients who receive a single dose into the detrusor of BTX-A (300 U or 200 U). The clinical outcome included maximum detrusor pressure (Pdetmax) during cystometry, voiding volume, urinary incontinence (UI) episodes between CICs per 24 hour, and complete dryness.Related adverse events were recorded. Results: From July 2015 to June 2017, 28 cases received 300 U BTX-A injections(experiment group) while 19 cases received 200U BTX-A injections(control group). There were no significant differences in baseline evaluation items (gender, age, duration of spinal cord injury, level of neurological injury, AIS scores) between the two groups. There were significant improvement in Pdetmax, UI and I-QoL from baseline in the two groups. Patients in experiment group had statistically greater improvement than those in the control group for Pdetmax (-32.09 cmH2O vs. -28.02 cmH2O, P = 0.016), mean urinary incontinence episodes (-6.18/d vs. -5.01/d, P = 0.042), complete dryness (11 vs. 2, P = 0.031), mean voiding volume (160.52 ml vs. 133.66 ml, P <0.001), and I-QoL (28.53 vs. 20.41, P <0.001). Conclusion: Preliminary results indicate that 300 U BTX-A is more effective than 200 U BTX-A for SCI patients with NDO.

Keywords